Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	26	61.64	9.74	15.56
Short-Term Investments	115.82	12.02	0.25	0.55
Cash & Short-Term Investments	141.82	73.66	9.99	16.11
Cash Growth	64.24%	637.44%	-37.98%	-
Prepaid Expenses	2.95	0.31	0.25	0.32
Other Current Assets	-	0.16	0.13	0.07
Total Current Assets	144.77	74.14	10.37	16.49
Property, Plant & Equipment	0.52	0.74	0.16	0.25
Other Long-Term Assets	2.19	2.64	0.01	0.01
Total Assets	147.48	77.51	10.54	16.76
Accounts Payable	5.06	2.3	1.04	0.26
Accrued Expenses	4.84	2.29	0.24	0.24
Current Portion of Leases	0.42	0.34	0.11	0.1
Total Current Liabilities	10.31	4.93	1.38	0.6
Long-Term Leases	0.23	0.44	0.05	0.16
Other Long-Term Liabilities	0.01	0.03	0	0.02
Total Liabilities	10.55	5.39	1.43	0.78
Additional Paid-In Capital	218.93	3.68	2.94	2.61
Retained Earnings	-82	-58.33	-37.74	-30.53
Total Common Equity	136.93	-54.64	-34.8	-27.92
Shareholders' Equity	136.93	72.11	9.1	15.98
Total Liabilities & Equity	147.48	77.51	10.54	16.76
Total Debt	0.65	0.78	0.16	0.26
Net Cash (Debt)	141.18	72.88	9.83	15.84
Net Cash Growth	63.70%	641.67%	-37.97%	-
Net Cash Per Share	13.14	18.24	2.48	4.07
Filing Date Shares Outstanding	21.7	21.7	3.97	3.89
Total Common Shares Outstanding	21.7	4.07	3.97	3.89
Working Capital	134.46	69.21	8.99	15.9
Book Value Per Share	6.31	-13.44	-8.77	-7.18
Tangible Book Value	136.93	-54.64	-34.8	-27.92
Tangible Book Value Per Share	6.31	-13.44	-8.77	-7.18

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q